Immunovant, Inc. Q1 2027 Earnings Recap

Roivant's stock edged up modestly by 1.7% following a quiet quarter that met expectations without delivering clear catalysts to drive a stronger move. Investors appear to be in a wait-and-see mode ahead of several key data readouts and potential product launches slated for the second half of 2026.

Key Takeaways

• The quarter was described as “quiet,” with no new significant commercial or clinical breakthroughs reported.
• Brexpiprazole is on track for an imminent launch in dermatomyositis, pending FDA approval, with additional Phase III enrollment advancing in cutaneous sarcoidosis.
• Several important Phase III data milestones are expected in the second half of 2026 for brexpiprazole in indications including NIU, PH-ILD, and CLE.
• Progress continues on the Moderna settlement and ongoing litigation against Pfizer and BioNTech.
• Investors are likely awaiting the upcoming “busier” period in 2H26 and beyond, given the pipeline’s heavy event schedule.